HDAC9 and Miyoshi myopathy: Panobinostat is a broad-spectrum HDAC inhibitor (HDACi) that has been FDA approved for use in refractory/relapsed MM (RRMM) in combination with bortezomib and dexamethasone based on favorable clinical trial results demonstrating a 35% overall response rate (ORR) [95].